Human Genome (HGSI) options expensive into Phase Three data
Down)
Human Genome (Nasdaq: HGSI) : Human Genome-HGSI is recently down 7c to $2.51. HGSI is expected to report top-line Phase three BLISS-56 data on LymphoStat-B is expected in July. HGSI call option volume of 6,925 contracts compares to put volume of 1,209 contracts. HGSI July 2.5 straddle is at $1.20, August 2.5 straddle is priced at $1.90 according to Track Data, suggesting large price movement. Paul Foster
You May Also Be Interested In
- Notable Analyst Rating Changes 05/24: (PPG) (WPI) (DUK) Upgraded; (BHI) (HGSI) (COG) Downgraded
- OpenTable (OPEN) Volatility Elevated with Shares Pressured; Bumps Up Against 50-Day SMA
- Star Scientific (CIGX) Shows Strength on Move Above Key Level
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
